MCID: DBT010
MIFTS: 60

Diabetic Neuropathy

Categories: Blood diseases, Eye diseases, Neuronal diseases

Aliases & Classifications for Diabetic Neuropathy

MalaCards integrated aliases for Diabetic Neuropathy:

Name: Diabetic Neuropathy 39 12 77 55 38 15 17
Diabetic Neuropathies 56 74

Classifications:



External Ids:

Disease Ontology 12 DOID:9743
KEGG 38 H01459
ICD9CM 36 250.6
MeSH 45 D003929
NCIt 51 C26748
SNOMED-CT 69 866003
UMLS 74 C0011882

Summaries for Diabetic Neuropathy

NINDS : 55 Diabetic neuropathy is a peripheral nerve disorder caused by diabetes or poor blood sugar control. The most common types of diabetic neuropathy result in problems with sensation in the feet. It can develop slowly after many years of diabetes or may occur early in the disease. The symptoms are numbness, pain, or tingling in the feet or lower legs. The pain can be intense and require treatment to relieve the discomfort. The loss of sensation in the feet may also increase the possibility that foot injuries will go unnoticed and develop into ulcers or lesions that become infected. In some cases, diabetic neuropathy can be associated with difficulty walking and some weakness in the foot muscles. There are other types of diabetic-related neuropathies that affect specific parts of the body. For example, diabetic amyotrophy causes pain, weakness and wasting of the thigh muscles, or cranial nerve infarcts that may result in double vision, a drooping eyelid, or dizziness. Diabetes can also affect the autonomic nerves that control blood pressure, the digestive tract, bladder function, and sexual organs. Problems with the autonomic nerves may cause lightheadedness, indigestion, diarrhea or constipation, difficulty with bladder control, and impotence.

MalaCards based summary : Diabetic Neuropathy, also known as diabetic neuropathies, is related to microvascular complications of diabetes 1 and diabetic autonomic neuropathy, and has symptoms including sciatica and neuralgia. An important gene associated with Diabetic Neuropathy is ACE (Angiotensin I Converting Enzyme), and among its related pathways/superpathways are AGE-RAGE signaling pathway in diabetic complications and p70S6K Signaling. The drugs Pregabalin and AT-101 have been mentioned in the context of this disorder. Affiliated tissues include skin, testes and bone, and related phenotypes are behavior/neurological and homeostasis/metabolism

Wikipedia : 77 Diabetic neuropathies are nerve damaging disorders associated with diabetes mellitus. These conditions... more...

Related Diseases for Diabetic Neuropathy

Diseases related to Diabetic Neuropathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 163)
# Related Disease Score Top Affiliating Genes
1 microvascular complications of diabetes 1 32.8 AKR1B1 INS NTF3 VEGFA
2 diabetic autonomic neuropathy 32.4 AKR1B1 EPO INS NGF NTF3
3 neuropathy 31.8 MPZ NGF PMP22 SCN9A
4 microvascular complications of diabetes 5 31.7 ACE AGER AKR1B1 INS PRKCB VEGFA
5 polyneuropathy 30.6 AKR1B1 MPZ PMP22
6 diabetes mellitus 30.3 ACE AGER AKR1B1 EPO INS SOD2
7 vascular disease 30.3 ACE AGER INS VEGFA
8 ischemia 30.2 ACE EPO SOD2 TRPV1 VEGFA
9 carpal tunnel syndrome 30.1 INS PMP22 VEGFA
10 diabetic polyneuropathy 29.9 AGER AKR1B1 NGF NTF3 SOD2 VEGFA
11 algoneurodystrophy 29.8 CALCA NGF
12 arteries, anomalies of 29.7 ACE INS TRPV1 VEGFA
13 autonomic neuropathy 29.2 AKR1B1 INS NGF NTRK1 SCN9A
14 peripheral nervous system disease 29.1 AKR1B1 INS MPZ NGF PMP22 SCN9A
15 microvascular complications of diabetes 3 11.3
16 microvascular complications of diabetes 4 11.3
17 microvascular complications of diabetes 6 11.3
18 microvascular complications of diabetes 7 11.3
19 microvascular complications of diabetes 2 11.0
20 abducens nerve disease 11.0
21 argyll robertson pupil 11.0
22 syncope 11.0
23 fainting 11.0
24 hypertensive encephalopathy 10.3 ACE EPO
25 severe nonproliferative diabetic retinopathy 10.3 INS VEGFA
26 renal artery disease 10.3 ACE EPO
27 lesion of sciatic nerve 10.3 NGF TRPV1
28 hypoglycemic coma 10.3 INS NTF3 VEGFA
29 opiate dependence 10.3 NGF TRPV1 VEGFA
30 adenomyosis 10.2 NGF TRPV1 VEGFA
31 mononeuritis of lower limb 10.2 PMP22 TRPV1
32 congenital hypomyelination neuropathy 10.2 MPZ PMP22
33 cough variant asthma 10.2 NGF TRPV1
34 gonadal disease 10.2 INS PARP1 VEGFA
35 charcot-marie-tooth hereditary neuropathy 10.2 MPZ PMP22
36 female reproductive system disease 10.2 PARP1 TRPV1 VEGFA
37 reproductive system disease 10.2 PARP1 TRPV1 VEGFA
38 diabetic angiopathy 10.2 AGER INS SOD2
39 glucose metabolism disease 10.2 ACE INS TRPV1
40 foot drop 10.2 MPZ PMP22
41 retinal vascular disease 10.2 ACE AKR1B1 INS VEGFA
42 depression 10.2
43 autosomal genetic disease 10.2 INS TRPV1 VEGFA
44 acquired metabolic disease 10.2 ACE INS TRPV1
45 roussy-levy hereditary areflexic dystasia 10.2 MPZ PMP22
46 charcot-marie-tooth disease, demyelinating, type 1f 10.2 MPZ PMP22
47 duodenal somatostatinoma 10.1 CALCA INS
48 postherpetic neuralgia 10.1
49 burning mouth syndrome 10.1 NGF SCN9A TRPV1
50 paroxysmal extreme pain disorder 10.1 SCN9A TRPV1

Graphical network of the top 20 diseases related to Diabetic Neuropathy:



Diseases related to Diabetic Neuropathy

Symptoms & Phenotypes for Diabetic Neuropathy

UMLS symptoms related to Diabetic Neuropathy:


sciatica, neuralgia

MGI Mouse Phenotypes related to Diabetic Neuropathy:

47 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.45 ACE AGER AKR1B1 CNTF INS MPZ
2 homeostasis/metabolism MP:0005376 10.38 ACE AGER AKR1B1 CNTF EPO GLO1
3 growth/size/body region MP:0005378 10.32 ACE AGER AKR1B1 INS NGF NTF3
4 immune system MP:0005387 10.27 ACE AGER CNTF EPO INS MPZ
5 cardiovascular system MP:0005385 10.24 ACE AGER EPO INS NGF NTF3
6 hematopoietic system MP:0005397 10.24 ACE AGER CNTF EPO INS MPZ
7 cellular MP:0005384 10.22 AGER CNTF EPO INS MPZ PARP1
8 mortality/aging MP:0010768 10.22 ACE AKR1B1 EPO INS MPZ NGF
9 integument MP:0010771 10.13 AGER EPO INS NGF NTRK1 PARP1
10 nervous system MP:0003631 10.13 CNTF INS MPZ NGF NTF3 NTRK1
11 muscle MP:0005369 10.07 AGER CNTF EPO INS NGF NTF3
12 no phenotypic analysis MP:0003012 9.8 CNTF INS NGF NTRK1 PARP1 TRPV1
13 normal MP:0002873 9.76 AGER EPO INS NGF NTF3 NTRK1
14 renal/urinary system MP:0005367 9.61 ACE AGER AKR1B1 INS PARP1 SCN9A
15 vision/eye MP:0005391 9.28 AKR1B1 INS NGF NTF3 NTRK1 PARP1

Drugs & Therapeutics for Diabetic Neuropathy

Drugs for Diabetic Neuropathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 498)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pregabalin Approved, Illicit, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 148553-50-8 5486971
2
AT-101 Approved, Investigational Phase 4,Phase 3 90141-22-3, 652-67-5 12597
3
Nitric Oxide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 10102-43-9 145068
4
Isosorbide Dinitrate Approved, Investigational Phase 4,Phase 3 87-33-2 6883
5
Saxagliptin Approved Phase 4 361442-04-8 11243969
6
Levofloxacin Approved, Investigational Phase 4,Phase 3,Phase 2 100986-85-4 149096
7
Linezolid Approved, Investigational Phase 4 165800-03-3 441401
8
Tazobactam Approved Phase 4,Phase 3 89786-04-9 123630
9
Ofloxacin Approved Phase 4,Phase 3,Phase 2 82419-36-1 4583
10
Aztreonam Approved Phase 4 78110-38-0 5742832 5362041
11
Piperacillin Approved Phase 4,Phase 3 66258-76-2 43672
12
Clavulanate Approved, Vet_approved Phase 4,Phase 3,Not Applicable 58001-44-8 5280980
13
Metronidazole Approved Phase 4 443-48-1 4173
14
Clindamycin Approved, Vet_approved Phase 4 18323-44-9 29029
15
Amoxicillin Approved, Vet_approved Phase 4,Phase 3,Not Applicable 26787-78-0 33613
16
Lidocaine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 137-58-6 3676
17
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 94-09-7, 1994-09-7 2337
18
tannic acid Approved Phase 4,Phase 3,Phase 2,Not Applicable 1401-55-4
19
Nabilone Approved, Investigational Phase 4,Phase 3 51022-71-0 5284592
20
Methylcobalamin Approved, Experimental, Investigational Phase 4,Phase 3,Not Applicable 13422-55-4
21
Hydroxocobalamin Approved Phase 4,Phase 3,Not Applicable 13422-51-0 11953898 15589840
22
leucovorin Approved Phase 4,Not Applicable 58-05-9 6006 143
23
Trimethoprim Approved, Vet_approved Phase 4,Not Applicable 738-70-5 5578
24
Ciprofloxacin Approved, Investigational Phase 4,Phase 1,Phase 2,Not Applicable 85721-33-1 2764
25
Sulfamethoxazole Approved Phase 4,Not Applicable 723-46-6 5329
26
Gabapentin Approved, Investigational Phase 4,Phase 3,Phase 2 60142-96-3 3446
27
Acetaminophen Approved Phase 4,Phase 3 103-90-2 1983
28
Tramadol Approved, Investigational Phase 4,Phase 3 27203-92-5 33741
29
Dopamine Approved Phase 4,Phase 3,Phase 2,Not Applicable 62-31-7, 51-61-6 681
30
Norepinephrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-41-2 439260
31
Amitriptyline Approved Phase 4,Phase 2,Not Applicable 50-48-6 2160
32
Sodium Citrate Approved, Investigational Phase 4,Phase 3,Not Applicable 68-04-2
33
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
34
Bromocriptine Approved, Investigational Phase 4 25614-03-3 31101
35
Quinapril Approved, Investigational Phase 4 85441-61-8 54892
36
Acetylcholine Approved, Investigational Phase 4,Phase 2,Not Applicable 51-84-3 187
37
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
38
Irbesartan Approved, Investigational Phase 4 138402-11-6 3749
39
Atorvastatin Approved Phase 4,Phase 2 134523-00-5 60823
40
Indapamide Approved Phase 4 26807-65-8 3702
41
Cefotaxime Approved Phase 4 63527-52-6 456256 5742673
42
Ceftriaxone Approved Phase 4 73384-59-5 5479530 5361919
43
Rifampicin Approved Phase 4 13292-46-1 5381226 5458213
44
Fusidic Acid Approved, Investigational Phase 4,Early Phase 1 6990-06-3 3000226
45
Cefepime Approved, Investigational Phase 4 88040-23-7 5479537
46
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1 564-25-0 54671203
47
Cefoxitin Approved Phase 4 35607-66-0 441199
48
Chlorhexidine Approved, Vet_approved Phase 4,Phase 2,Not Applicable 55-56-1 2713 9552079
49
Petrolatum Approved, Investigational Phase 4,Phase 2 8009-03-8
50
Sultamicillin Approved, Investigational Phase 4 76497-13-7

Interventional clinical trials:

(show top 50) (show all 932)
# Name Status NCT ID Phase Drugs
1 Evaluation of the Impact of Training on Outcome Measures in Subjects With Painful Diabetic Neuropathy Unknown status NCT01770964 Phase 4 Pregabalin;placebo
2 Bi-Axial Rotating Magnetic Field Therapy in Refractory Neuropathic Foot Pain Secondary to Diabetic Peripheral Neuropathy Unknown status NCT00123136 Phase 4
3 Influence of Nitrates on Bone Remodeling and Endothelial Function in Patients With Type 2 Diabetes Mellitus Unknown status NCT02011620 Phase 4
4 Inspiratory Muscle Training in Patients With Autonomic Neuropathic Unknown status NCT00752440 Phase 4
5 Maggot Debridement Therapy Versus Conventional Dressing Therapy to Treat Diabetic Foot Ulcers Unknown status NCT02816749 Phase 4
6 Dipeptidyl Peptidase 4 Inhibition Facilitate Healing of Diabetic Ulcers Unknown status NCT02742233 Phase 4 saxagliptin;placebo
7 A Comparative Efficacy Study of DermaPure™ to Treat Diabetic Foot Ulcers Unknown status NCT02081352 Phase 4
8 Efficacy and Safety of Garamycin® Sponge (Gentamicin-Collagen Sponge) in Diabetic Patients With a Moderate or Severe Foot Ulcer Infection Unknown status NCT01951768 Phase 4 Garamycin Sponge (Gentamicin-Collagen sponge);Systemic Antibiotic
9 Clinical Evaluation of the SNaP Wound Care System Unknown status NCT01113658 Phase 4
10 A Randomized Double-Blind Study Testing the Effects of Pregabalin on Diabetic Neuropathy Completed NCT00573261 Phase 4 Pregabalin;Placebo
11 Frequency Modulated Neural Stimulation (FREMS) in Symptomatic Diabetic Neuropathy Completed NCT01628627 Phase 4
12 A Study on the Efficacy and Safety of Gabapentin in the Treatment of Patients With Painful Diabetic Neuropathy Completed NCT00644748 Phase 4 gabapentin
13 A Study to Compare Safety and Efficacy of Tramadol Hydrochloride/Acetaminophen With Gabapentin in Participants With Diabetic Neuropathy Completed NCT00634543 Phase 4 Tramadol hydrochloride/ Acetaminophen;Gabapentin
14 Effect of Pulsing Electrical Fields on Lower Extremity Diabetic Neuropathy: A Pilot, Open-Label Study Completed NCT00614341 Phase 4
15 Alpha Lipoic Acid for Treatment of Diabetic Neuropathy Completed NCT02439879 Phase 4 Alpha lipoic acid
16 A Study of the Effectiveness And Safety Of Lidoderm® As Add-On Treatment in Patients With Postherpetic Neuralgia, Diabetic Neuropathy, or Low Back Pain Completed NCT00904020 Phase 4 Lidoderm
17 Maintenance of Effect of Duloxetine in Patients With Diabetic Peripheral Neuropathic Pain (DPNP) Completed NCT00322621 Phase 4 Duloxetine
18 Training "Pain Connoisseurs" for Efficient Analgesic Proof-of-Concept Studies Completed NCT02842554 Phase 4 Drug Placebo Administration
19 Evaluation of Rocker sOles in Diabetis Completed NCT02891928 Phase 4
20 Evaluation of the Efficacy of Cesamet™ for the Treatment of Pain in Patients With Diabetic Peripheral Neuropathy Completed NCT00380913 Phase 4 Cesamet™ (nabilone)
21 Tolerability of Switching to Duloxetine for the Management of Diabetic Nerve Pain Completed NCT00266643 Phase 4 duloxetine hydrochloride
22 An Open Label, Dose Finding Trial of Viagra for the Treatment of Neuropathic Pain (in Diabetes Mellitus) Completed NCT00194909 Phase 4 sildenafil (Viagra)
23 An Open-Label Comparison of Duloxetine to Other Alternatives for the Management of Diabetic Peripheral Neuropathic Pain Completed NCT00385671 Phase 4 duloxetine hydrochloride;pregabalin;gabapentin
24 Pregabalin in the Treatment of Pain Due to Diabetic Peripheral Neuropathy Completed NCT00159679 Phase 4 Pregabalin
25 A Study To Evaluate Pregabalin In Patients With Painful Diabetic Peripheral Neuropathy (DPN) Completed NCT00156078 Phase 4 pregabalin
26 A Study of the Efficacy and Safety of Pregabalin for the Treatment of Diabetic Peripheral Neuropathy or Postherpetic Neuralgia Completed NCT00629681 Phase 4 Pregabalin
27 Lovaza® and Microvascular Function in Type 2 Diabetes Completed NCT00931879 Phase 4 omega-3-ethyl esters;Placebo
28 Anodyne Therapy in Diabetic Sensory Neuropathy Completed NCT00120341 Phase 4
29 Efficacy and Tolerability of Carbamazepine CR in Diabetic Neuropathy Pain Completed NCT01089855 Phase 4 Carbamazepine
30 Duloxetine in Patients With Diabetic in Peripheral Neuropathic Pain With or Without Co-morbid Major Depressive Disorder Completed NCT00844194 Phase 4 Duloxetine 60 mg QD;Duloxetine 60 mg QD;Duloxetine 30 mg QD;Duloxetine 30 mg QD;Duloxetine 90 mg QD;Duloxetine 90 mg QD;Duloxetine 60 mg QD;Duloxetine 60 mg QD;Duloxetine 120 mg QD;Duloxetine 30 mg QD;Duloxetine 30 mg QD;Duloxetine 120 mg QD
31 PRELIMINARY EVALUATION OF PHARMACOLOGICAL LOWERING OF AGEs Completed NCT02249897 Phase 4 CHOLESTYRAMINE
32 A Study Of Lidocaine Patch 5% Alone, Gabapentin Alone, And Lidocaine Patch 5% And Gabapentin In Combination For The Relief Of Pain In Patients With Diverse Peripheral Neuropathic Pain Conditions Completed NCT00904202 Phase 4 Placebo Capsules + Placebo Patch;Placebo capsules + Lidoderm®;Gabapentin + Placebo;Gabapentin + Lidoderm®;Gabapentin 300 mg capsules 1800 mg/day + placebo patch;Gabapentin 1800 mg/day + Lidoderm patch
33 Lidoderm® (Lidocaine Patch 5%) in Diabetic and Idiopathic Neuropathy Completed NCT00903851 Phase 4 Lidoderm
34 Safety and Efficacy of Mecobalamin Injection in Peripheral Neuropathies Patients (Study JGAZSY091109) Completed NCT01192113 Phase 4 Mecobalamin IV Injection;Mecobalamin IM injection;Mecobalamin IV or IM injection
35 Bromocriptine-QR Therapy on Sympathetic Tone and Vascular Biology in Type 2 Diabetes Subjects Completed NCT02682901 Phase 4 Cycloset;Placebo
36 A Study of Duloxetine (LY248686) in Participants With Diabetic Peripheral Neuropathic Pain (DPNP) Completed NCT02417935 Phase 4 Duloxetine;Pregabalin;Placebo
37 Efficacy and Safety of Gabapentin/B-complex Versus Pregabalin in Diabetic Peripheral Neuropathy Pain Management Completed NCT01364298 Phase 4 Gabapentin/B-complex;Pregabalin
38 Study of Metanx® in Subjects With Type 2 Diabetic Peripheral Neuropathy (DPN) Completed NCT00726713 Phase 4
39 Safety of Pregabalin in the Treatment of Pain Due to Diabetic Peripheral Neuropathy Completed NCT00159731 Phase 4 Pregabalin
40 Study of Oasis Ultra in Diabetic Foot Ulcers Completed NCT01835379 Phase 4
41 Efficacy of Administration of ACE-Inhibition on Autonomic and Peripheral Neuropathy in Patients With Diabetes Mellitus Completed NCT03031834 Phase 4 Quinapril
42 Pregabalin Treatment Of Peripheral Neuropathic Pain Associated With Diabetic Peripheral NeP (DPN), Postherpetic Neuralgia (PHN), HIV-related NeP (HIV), and Chemotherapy Induced NeP Completed NCT00407511 Phase 4 Pregabalin
43 The InsuPad in Daily Life Study - Effect of Local Heating on Postprandial Glucose Excursions Using the InsuPad Device Completed NCT01352767 Phase 4
44 Botulinum Toxin in Peripheral Neuropathic Pain Completed NCT01251211 Phase 4 botulinum toxin type A
45 Renal Denervation in Diabetic Nephropathy Completed NCT01588795 Phase 4 Standardized antiproteinuric medication regimen includes an angiotensin receptor blocker , a diuretic , 25OH vitamin D3 and a statin
46 Pharmacokinetics of Two Formulation of Pregabalin Completed NCT03712475 Phase 4 Pregabalin
47 GrafixPRIME® for the Treatment of Chronic Diabetic Foot Ulcers Completed NCT02675855 Phase 4
48 Use of Santyl in Diabetic Foot Ulcers Completed NCT02581488 Phase 4
49 GrafixCORE®: Open-Label Study to Evaluate the Safety and Efficacy of GrafixCORE® for Complex Diabetic Foot Wounds Completed NCT02260609 Phase 4
50 LeucoPatch in the Management of Hard-to-heal Diabetic Foot Ulcers Completed NCT02224742 Phase 4

Search NIH Clinical Center for Diabetic Neuropathy

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Diabetic Neuropathy cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Diabetic Neuropathy:
Hematopoietic stem cells for limb ischemia and diabetic neuropathy
Embryonic/Adult Cultured Cells Related to Diabetic Neuropathy:
Peripheral blood-derived hematopoietic stem cells (family)

Genetic Tests for Diabetic Neuropathy

Anatomical Context for Diabetic Neuropathy

MalaCards organs/tissues related to Diabetic Neuropathy:

42
Skin, Testes, Bone, Endothelial, Spinal Cord, Bone Marrow, Heart

Publications for Diabetic Neuropathy

Articles related to Diabetic Neuropathy:

(show top 50) (show all 2480)
# Title Authors Year
1
Dyshidrosis associated with diabetes mellitus: Hypohidrosis associated with diabetic neuropathy and compensated hyperhidrosis. ( 30859595 )
2019
2
Surgical peripheral nerve decompression for the treatment of painful diabetic neuropathy of the foot - A level 1 pragmatic randomized controlled trial. ( 30081106 )
2019
3
Pregabalin in the Management of Painful Diabetic Neuropathy: A Narrative Review. ( 30565054 )
2019
4
Regional anaesthesia, diabetic neuropathy, and dexmedetomidine: a neurotoxic combination? ( 30579401 )
2019
5
Pathway crosstalk perturbation network modeling for identification of connectivity changes induced by diabetic neuropathy and pioglitazone. ( 30616626 )
2019
6
Dose vitamin D supplementations improve peripheral diabetic neuropathy? A before-after clinical trial. ( 30641826 )
2019
7
A cross-sectional study to estimate the point prevalence of painful diabetic neuropathy in Eastern Libya. ( 30654784 )
2019
8
3-Mercapto-5H-1,2,4-Triazino[5,6-b]Indole-5-Acetic Acid (Cemtirestat) Alleviates Symptoms of Peripheral Diabetic Neuropathy in Zucker Diabetic Fatty (ZDF) Rats: A Role of Aldose Reductase. ( 30689163 )
2019
9
Antihypernociceptive and neuroprotective effects of Combretin A and Combretin B on streptozotocin-induced diabetic neuropathy in mice. ( 30759263 )
2019
10
Lens autofluorescence ratio as a noninvasive marker of peripheral diabetic neuropathy. ( 30762026 )
2019
11
Investigation of the utility of Curcuma caesia in the treatment of diabetic neuropathy. ( 30767224 )
2019
12
Mechanism of the JAK2/STAT3-CAV-1-NR2B signaling pathway in painful diabetic neuropathy. ( 30830585 )
2019
13
Prevalence and risk factors for painful diabetic neuropathy in secondary health care in Qatar. ( 30860314 )
2019
14
Correction to: Pathway crosstalk perturbation network modeling for identification of connectivity changes induced by diabetic neuropathy and pioglitazone. ( 30866938 )
2019
15
INSoles To Ease Pressure (INSTEP) Study: a multicentre, randomised controlled feasibility study to compare the effectiveness of a novel instant optimised insole with a standard insole for people with diabetic neuropathy: a study protocol. ( 30904880 )
2019
16
Diabetic neuropathies influence recovery from hip-fracture surgery in older persons with diabetes. ( 30738920 )
2019
17
Cure of human diabetic neuropathy by HPLC validated bark extract of Onosma echioides L. root. ( 29629826 )
2018
18
Diabetic neuropathy and painful diabetic neuropathy: Cinderella complications in South East Asia. ( 29371725 )
2018
19
Single fiber F-waves compared with conventional surface F-waves, and their utility in detecting early diabetic neuropathy. ( 29975798 )
2018
20
Neuroprotective effect of duloxetine in a mouse model of diabetic neuropathy: Role of glia suppressing mechanisms. ( 29763613 )
2018
21
Comparison of peripheral nerve blockade characteristics between non-diabetic patients and patients suffering from diabetic neuropathy: a prospective cohort study. ( 29858510 )
2018
22
Adenosine monophosphate-activated protein kinase modulation by berberine attenuates mitochondrial deficits and redox imbalance in experimental diabetic neuropathy. ( 29273519 )
2018
23
Cerebral Biochemical Effect of Pregabalin in Patients with Painful Diabetic Neuropathy: A Randomized Controlled Trial. ( 29951977 )
2018
24
Feasibility and effectiveness of electrochemical dermal conductance measurement for the screening of diabetic neuropathy in primary care. DECODING Study (Dermal Electrochemical Conductance in Diabetic Neuropathy). Rationale and design. ( 29768354 )
2018
25
Hearing Loss in Type 2 Diabetes in Association with Diabetic Neuropathy. ( 29433858 )
2018
26
Tanshinone IIA Improves Painful Diabetic Neuropathy by Suppressing the Expression and Activity of Voltage-Gated Sodium Channel in Rat Dorsal Root Ganglia. ( 29388177 )
2018
27
Fluoxetine pretreatment enhances neurogenic, angiogenic and immunomodulatory effects of MSCs on experimentally induced diabetic neuropathy. ( 29687216 )
2018
28
Neuropathic pain drives anxiety behavior in mice, results consistent with anxiety levels in diabetic neuropathy patients. ( 29922743 )
2018
29
Transcriptome analysis of dorsal root ganglia's diabetic neuropathy reveals mechanisms involved in pain and regeneration. ( 29750992 )
2018
30
Phloretin either alone or in combination with duloxetine alleviates the STZ-induced diabetic neuropathy in rats. ( 29635891 )
2018
31
The H-Reflex as a Biomarker for Spinal Disinhibition in Painful Diabetic Neuropathy. ( 29362940 )
2018
32
Diabetic neuropathy differs between type 1 and type 2 diabetes Insights from magnetic resonance neurography. ( 29443416 )
2018
33
Molecular mechanism of diabetic neuropathy and its pharmacotherapeutic targets. ( 29966615 )
2018
34
Peripheral Glial Cells in the Development of Diabetic Neuropathy. ( 29770116 )
2018
35
Altered Achilles tendon function during walking in people with diabetic neuropathy: implications for metabolic energy saving. ( 29420151 )
2018
36
Gene therapy with the angiogenic neuropeptide secretoneurin ameliorates experimental diabetic neuropathy. ( 29913555 )
2018
37
Bone marrow-derived mesenchymal stem/stromal cells reverse the sensorial diabetic neuropathy via modulation of spinal neuroinflammatory cascades. ( 29933760 )
2018
38
Pharmacodynamics and Pharmacokinetics of Lidocaine in a Rodent Model of Diabetic Neuropathy. ( 29251644 )
2018
39
The correlation between obstructive sleep apnea and diabetic neuropathy: A meta-analysis. ( 29728306 )
2018
40
Nebivolol, a I^-blocker abrogates streptozotocin-induced behavioral, biochemical, and neurophysiological deficit by attenuating oxidative-nitrosative stress: a possible target for the prevention of diabetic neuropathy. ( 29322226 )
2018
41
Expression of macrophage migration inhibitory factor in footpad skin lesions with diabetic neuropathy. ( 29690804 )
2018
42
[EXPRESS] Auricular vagus nerve stimulation enhances central serotonergic function and inhibits diabetic neuropathy development in Zucker fatty rats. ( 29921169 )
2018
43
Preclinical assessment of utility of M6S for multimodal acute and chronic pain treatment in diabetic neuropathy. ( 29191644 )
2018
44
Diabetic Neuropathy - situational analysis in Pakistan. ( 29371708 )
2018
45
Neuroprotective and antinociceptive effects of rosemary (Rosmarinus officinalis L.) extract in rats with painful diabetic neuropathy. ( 29754274 )
2018
46
Axonal transport in a peripheral diabetic neuropathy model: sex-dimorphic features. ( 29351809 )
2018
47
Gangrenous cholecystitis: A silent but potential fatal disease in patients with diabetic neuropathy. A case report. ( 30568955 )
2018
48
Diabetic Neuropathy Prevalence and Its Associated Risk Factors in Two Representative Groups of Type 1 and Type 2 Diabetes Mellitus Patients from Bihor County. ( 30568743 )
2018
49
Characterization of diabetic neuropathy progression in a mouse model of type 2 diabetes mellitus. ( 30082375 )
2018
50
Negative Regulation of TRPA1 by AMPK in Primary Sensory Neurons as a Potential Mechanism of Painful Diabetic Neuropathy. ( 29025860 )
2018

Variations for Diabetic Neuropathy

Expression for Diabetic Neuropathy

Search GEO for disease gene expression data for Diabetic Neuropathy.

Pathways for Diabetic Neuropathy

Pathways related to Diabetic Neuropathy according to KEGG:

38
# Name Kegg Source Accession
1 AGE-RAGE signaling pathway in diabetic complications hsa04933

Pathways related to Diabetic Neuropathy according to GeneCards Suite gene sharing:

(show all 14)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.84 ACE INS NGF NTF3 NTRK1 PRKCB
2
Show member pathways
12.75 EPO INS NGF NTF3 NTRK1 VEGFA
3 12.47 INS NGF NTF3 NTRK1 PRKCB VEGFA
4
Show member pathways
12.38 INS NGF NTF3 NTRK1 PRKCB VEGFA
5
Show member pathways
12.22 NGF NTRK1 PARP1 PRKCB TRPV1 VEGFA
6 11.71 AGER PRKCB VEGFA
7 11.67 EPO INS PRKCB VEGFA
8 11.49 AGER INS PRKCB
9
Show member pathways
11.42 NGF NTF3 NTRK1
10 11.23 NGF NTF3 NTRK1
11 11.15 CNTF NGF NTF3 VEGFA
12 11.12 INS PARP1 PRKCB
13 10.61 CNTF EPO INS VEGFA
14
Show member pathways
10.55 NGF NTRK1

GO Terms for Diabetic Neuropathy

Cellular components related to Diabetic Neuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.81 ACE AGER CALCA CNTF EPO INS
2 extracellular space GO:0005615 9.61 ACE AKR1B1 CALCA CNTF EPO INS
3 axon GO:0030424 9.1 CALCA CNTF NGF NTF3 NTRK1 SCN9A

Biological processes related to Diabetic Neuropathy according to GeneCards Suite gene sharing:

(show all 26)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell migration GO:0030335 9.88 INS NTF3 SOD2 VEGFA
2 aging GO:0007568 9.84 CALCA EPO NTRK1 SOD2
3 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.8 AGER INS NTRK1 PRKCB
4 negative regulation of apoptotic process GO:0043066 9.8 AKR1B1 EPO GLO1 MPZ NGF NTRK1
5 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.79 NGF NTF3 NTRK1
6 activation of protein kinase activity GO:0032147 9.78 CALCA EPO VEGFA
7 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.74 CNTF EPO VEGFA
8 regulation of blood pressure GO:0008217 9.73 ACE CALCA SOD2
9 sensory perception of pain GO:0019233 9.72 NTRK1 SCN9A TRPV1
10 cellular response to nerve growth factor stimulus GO:1990090 9.65 CALCA NTRK1 TRPV1
11 positive regulation of vascular endothelial growth factor receptor signaling pathway GO:0030949 9.63 PRKCB VEGFA
12 cellular response to amyloid-beta GO:1904646 9.63 AGER NTRK1 PARP1
13 macrophage differentiation GO:0030225 9.62 PARP1 VEGFA
14 nerve development GO:0021675 9.61 NGF NTF3
15 peripheral nervous system development GO:0007422 9.61 NGF NTF3 PMP22
16 negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway GO:1902176 9.59 INS SOD2
17 behavioral response to pain GO:0048266 9.58 SCN9A TRPV1
18 positive regulation of Ras protein signal transduction GO:0046579 9.58 EPO NGF NTRK1
19 detection of temperature stimulus involved in sensory perception of pain GO:0050965 9.54 CALCA NTRK1 TRPV1
20 negative regulation of calcium ion transport into cytosol GO:0010523 9.52 CALCA EPO
21 positive regulation of peptidyl-tyrosine autophosphorylation GO:1900086 9.51 ACE VEGFA
22 induction of positive chemotaxis GO:0050930 9.5 AGER NTF3 VEGFA
23 negative regulation of neuron apoptotic process GO:0043524 9.35 CNTF NGF NTF3 NTRK1 SOD2
24 nerve growth factor signaling pathway GO:0038180 9.33 NGF NTF3 NTRK1
25 regulation of signaling receptor activity GO:0010469 9.17 CALCA CNTF EPO INS NGF NTF3
26 positive regulation of cell proliferation GO:0008284 10 CNTF EPO INS NTF3 VEGFA

Molecular functions related to Diabetic Neuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.5 AGER CALCA INS PARP1 SOD2 TRPV1
2 hormone activity GO:0005179 9.33 CALCA EPO INS
3 growth factor activity GO:0008083 8.92 CNTF NGF NTF3 VEGFA

Sources for Diabetic Neuropathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT